Navigation Links
Gene expression patterns predict rapid decline in idiopathic pulmonary fibrosis patients

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease typically characterized by the slow but progressive onset of shortness of breath or cough. Most patients live about five years after diagnosis. However, according to a new study being published today in the online journal PLoS ONE, a subset of patients with a specific genetic profile has a much more rapid progression to complete pulmonary failure and death without a lung transplant.

Based on observations in the clinic that some IPF patients display a more rapidly progressing disease course, researchers at the Simmons Center for Interstitial Lung Disease at the University of Pittsburgh School of Medicine, collaborating with pulmonary scientists in Mexico and California, used DNA microarray analysis to measure the gene expression patterns of 26 rapid progressors and 88 slow progressors. They identified 437 differentially expressed genes between the groups. Specifically, lungs of rapid progressors, who were predominantly males who smoked, overexpressed genes involved in the development of tissues and organs (morphogenesis), oxidative stress, cell migration and proliferation and genes from fibroblasts and smooth muscle cells.

According to Naftali Kaminski, M.D., director of the Simmons Center and director of the Lung Translational Genomics Center, division of pulmonary, allergy and critical care medicine, University of Pittsburgh School of Medicine, these findings offer strong evidence that rapid progressors represent a distinct clinical phenotype compared with the usual slower progressing patients.

"We are only now starting to really understand IPF and to characterize it," Dr. Kaminski said. "Therefore, it is critical for patients with the disease to be seen in centers that are actively involved in IPF research, so we can help them better decide a course of action."

These findings also highlight the variability in the progression and outcome of IPF and may explain, in part, the difficulty in obtaining significant and reproducible results in studies of therapeutic interventions in patients with IPF, noted first author Moisés Selman, M.D., director of research at the National Institute of Respiratory Research in Mexico City. "This study suggests that physicians should pay more attention to the time of onset of symptoms in their patients," Dr. Selman said.

"Although preliminary, these results may allow investigators to identify biomarkers of disease progression and, more importantly, better evaluate the effectiveness of potential therapies," added Talmadge E. King Jr., M.D., chief of medicine at San Francisco General Hospital and an internationally renowned expert in research and management of pulmonary fibrosis.
'"/>

Source:University of Pittsburgh Schools of the Health Sciences


Related biology news :

1. Alcohols effects on gene expression in the central nervous system
2. Carnegie Mellon scientists develop tool that uses MRI to visualize gene expression in living animals
3. Towards precise classification of cancers based on robust gene functional expression profiles
4. Expression Project for Oncology (expO) completes first phase of standardized gene expression analyses
5. Study: homemade gene expression technology unreliable
6. Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression
7. Agilent Technologies releases probe sequence, annotation information for all its commercial gene expression microarrays
8. Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia
9. Computational verification of protein-protein interactions by orthologous co-expression
10. Random gene expression may drive HIV into hiding
11. Confirmation of human protein interaction data by human expression data

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: